A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.
Also called NCT02087917
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 376 participants
- Sponsor
- Registry
-
NCT02087917
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02087917. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2014-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
- Condition
- Primary Hypercholesterolemia
- Intervention (Drug)
- HS-25
- Intervention (Drug)
- Placebo
- Lead sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Collaborator
- Covance
Record details
- Record id
cardio:ct-nct02087917- Content hash
ed66e24f783583a0293254d06ad9f6e5f15ea2be4d9f976710accc500edc4841